Company: REVB
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001193125-25-269450
Chunk: 4

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 2
Chunk 4
---
,325      (6,499,226       (6,221,221       (278,005  
  Total other income (expense), net                                  35,835        (444,879       480,714          96,583       (7,091,596      7,188,179  
  Net loss                               $                       (1,907,176      (2,241,565       334,389      (6,402,643      (13,312,817      6,910,174  

Research and Development Expenses

The following table summarizes our research and development expenses for the periods presented:

                                                               Three Months Ended                                                                                   
                                                               September 30,                                                                                        
                                                               2025                                                                                                 
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  GEM-AKI, GEM-CKD and GEM-PSI clinical study expenses         $                       572,250      498,923      73,327      2,004,255      1,950,421       53,834  
  Other expenses                                                                        24,897       22,447       2,450         69,080         72,946       (3,866  
  Personnel expenses (including stock-based compensation)                              325,710      309,611      16,099      1,026,332        920,125      106,207  
  Total research and development expenses                      $                       922,857      830,981      91,876      3,099,667      2,943,492      156,175  

Research and development expenses increased by $0.1 million, from $0.8 million for the three months ended September 30, 2024 to $0.9 million for the three months ended September 30, 2025. The increase was primarily due to an increase in clinical study expenses related to our Product Candidates.

Research and development expenses increased by $0.2 million, from $2.9 million for the nine months ended September 30, 2024 to $3.1 million for the nine months ended September 30, 2025. The increase was due to increases in personnel expenses of $0.1 million and $0.1 million of clinical study expenses related to our Product Candidates.

General and Administrative Expenses

General and administrative expenses for the three months ended